Revised SPCs: Ropilynz (ropinirole hydrochloride) XL Prolonged-release Tablets (all strengths)

To discontinue treatment in patients with Parkinson's disease, ropinirole should be tapered off, as patients with impulse control disorders and those receiving high daily dose and/or cumulative doses may be at higher risk for developing dopamine agonist withdrawal syndrome.

Source:

electronic Medicines compendium